- $183.77m
- $58.47m
- $72.76m
Cancer drugmakers gain after Roche discloses positive data from drug study
Brief: Compugen Says Co Wins On PVRIG European Patent Opposition Pursued by GSK and a Third Party
Brief: Compugen Doses First Patient In Triple Immunotherapy Combination COM701, COM902 And Pembrolizumab Platinum Resistant Ovarian Cancer Proof-Of-Concept Study
Brief: Compugen Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Compugen Reports First Quarter 2023 Results
Brief: Compugen To Present New Clinical Data On COM701 Triple Combination
Brief: Compugen Ltd Files For Mixed Shelf Of Up To $350 Million – SEC Filing
Israel stocks slip on SVB failure, government vows aid for tech firms (updated)
Brief: Compugen Doses First Patient In Triple Combination Com701, Com902 And Pembrolizumab Mss Crc Proof-Of-Concept Study
Brief: Compugen Reports Q4 Loss Per Share Of $0.04
Brief: Rilvegostomig, Astrazeneca's Bi-Specific Antibody Derived From Compugen's Com902, Expected To Progress Into Phase 3
Brief: Compugen Ltd May Offer, Sell Ordinary Shares Of Up To $50 Million From Time To Time Through Svb Securities
Brief: Compugen's COM701(Anti-PVRIG)In Dual And Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity And Immune Activation In Patients With Platinum Resistant Ovarian Cancer
Brief: Compugen's Com701 In Combination Demonstrates Preliminary Anti-Tumor Activity In Ovarian Cancer Patients
Compugen rises on expectations of $7.5 mln drug milestone payment
Brief: Compugen To Receive Milestone Payment Triggered By Astrazeneca's Phase 2 Initiation Of Pd-1/Tigit Bispecific
Brief: Compugen Reports Third Quarter 2022 Results
Brief: Compugen's Com701 Anti-Pvrig Induces Potent Immune Activation In Mss-Crc Patients
Brief: Compugen Receives Notification Letter From Listing Qualifications Department Of Nasdaq